• For investors considering whether Guardant Health at around US$87.60 represents fair value or a potential opportunity, this article examines what that price may indicate about the stock.
• The share price is US$87.60 after a 1.5% decline over the past week and a 3.9% decline over the past month. It is still up 87.0% over the past year and 270.4% over three years, while a 35.3% decline over five years provides additional context.
• Recent news about Guardant Health has highlighted its role in healthcare and diagnostics, which has kept attention on how its technology and market position might influence long term expectations. That backdrop helps explain why the stock has experienced both strong multi year returns and shorter term pullbacks.
• Guardant Health currently has a valuation score of 3 out of 6. The rest of this article will outline what that means across different valuation methods before concluding with a more comprehensive way to think about the stock's value.

Approach 1: Guardant Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to the present. It is essentially asking what Guardant Health’s future cash generation might be worth in today’s dollars.

For Guardant Health, the latest twelve month free cash flow is a loss of about US$229.4 million. Analysts provide explicit free cash flow estimates out to 2030, and Simply Wall St extrapolates further years. Under this 2 Stage Free Cash Flow to Equity model, projected free cash flow reaches US$571 million in 2030, with additional projections through 2035 helping shape the long term picture.

When all these projected cash flows are discounted back using the DCF approach, the estimated intrinsic value comes out at roughly US$173.89 per share. Compared with the current share price of US$87.60, this suggests the stock could be about 49.6% undervalued based on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Guardant Health is undervalued by 49.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Guardant Health Price vs Sales

For companies where earnings are not yet positive, the P/S ratio is often a more practical yardstick because it focuses on revenue rather than profit. It lets you compare what investors are paying for each dollar of sales, which can be useful when profits are still some way off or volatile.

Growth expectations and risk both influence what a normal or fair P/S might look like. Higher expected growth and lower perceived risk can support a higher multiple, while slower growth and higher uncertainty typically align with a lower one.

Guardant Health currently trades on a P/S of 11.70x. That sits well above the Healthcare industry average of about 1.21x and the peer average of 1.24x. Simply Wall St’s Fair Ratio for Guardant Health is 5.38x, which is a proprietary estimate of what the P/S might be given the company’s earnings growth profile, industry, profit margins, market cap and risk factors.

This Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for Guardant Health’s specific growth outlook, risk level, profitability and size. Comparing the Fair Ratio of 5.38x with the current 11.70x suggests the shares trade above this modelled level.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardant Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story behind the numbers by linking your view of Guardant Health’s business to a specific forecast and a fair value, then comparing that fair value to today’s price to help you judge whether it looks attractive or stretched.

Each Narrative on the Community page is easy to use. It shows how assumptions about future revenue, earnings and margins flow into a valuation that updates automatically when fresh news or earnings arrive, so your view never sits frozen in time.

For Guardant Health, one investor might align with the more optimistic Narrative that points to a fair value near US$140.00. Another might prefer a more cautious Narrative closer to US$82.18, and seeing those side by side helps you decide which story and valuation feels more realistic for your own decision making.

For Guardant Health however we will make it really easy for you with previews of two leading Guardant Health Narratives:

Fair value: US$128.33

Implied undervaluation versus the current US$87.60 price: about 31.8%.

Revenue growth assumption: 28.05% a year.

• Analysts frame Guardant Health as a growing precision oncology business, with blood based cancer diagnostics, multi cancer detection and MRD all feeding into a larger market opportunity.
• The bullish view ties strong demand, demographic trends and expanding clinical validation to higher long term revenue, margin improvement and a path toward profitability, while accepting that spending and reimbursement remain key swing factors.
• The consensus target of US$128.33 rests on revenue reaching about US$2.1b and earnings of roughly US$105.5m by 2029, on a projected P/E of about 231.8x. It therefore assumes investors will still accept a high multiple on those future earnings.

Fair value: US$82.18

Implied overvaluation versus the current US$87.60 price: about 6.6%.

Revenue growth assumption: 24.58% a year.

• The more cautious narrative highlights Guardant Health’s reliance on premium pricing and ongoing heavy investment, with concerns that slower screening uptake or reimbursement progress could weigh on margins and cash flow for longer.
• Bearish analysts still factor in revenue and earnings growth over time, but argue that the P/E multiple needed to justify higher prices is demanding relative to the wider US Healthcare sector and leaves limited room for disappointment.
• The implied fair value of US$82.18 reflects assumptions of revenue of about US$1.7b and earnings of roughly US$95.2m by 2029 on a P/E of about 141.9x. This camp views that as a more cautious way to price the same set of opportunities and risks.

If you want to weigh these viewpoints directly against live numbers, the Community Narratives give you the full logic, forecasts and valuation inputs that sit behind each storyline for Guardant Health, so you can decide which one feels closest to your own expectations.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Guardant Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Guardant Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.